Your browser doesn't support javascript.
loading
Current knowledge, challenges and innovations in developmental pharmacology: A combined conect4children Expert Group and European Society for Developmental, Perinatal and Paediatric Pharmacology White Paper.
Smits, Anne; Annaert, Pieter; Cavallaro, Giacomo; De Cock, Pieter A J G; de Wildt, Saskia N; Kindblom, Jenny M; Lagler, Florian B; Moreno, Carmen; Pokorna, Paula; Schreuder, Michiel F; Standing, Joseph F; Turner, Mark A; Vitiello, Benedetto; Zhao, Wei; Weingberg, Annelie-Martina; Willmann, Raffaella; van den Anker, John; Allegaert, Karel.
Afiliação
  • Smits A; Department of Development and Regeneration, KU Leuven, Leuven, Belgium.
  • Annaert P; Neonatal intensive Care unit, University Hospitals Leuven, Leuven, Belgium.
  • Cavallaro G; Drug Delivery and Disposition, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
  • De Cock PAJG; Neonatal intensive care unit, Fondazione IRCCS Ca' Grande Ospedale Maggiore Policlinico, Milan, Italy.
  • de Wildt SN; Department of Pediatric Intensive Care, Ghent University Hospital, Ghent, Belgium.
  • Kindblom JM; Heymans Institute of Pharmacology, Ghent University, Ghent, Belgium.
  • Lagler FB; Department of Pharmacy, Ghent University Hospital, Ghent, Belgium.
  • Moreno C; Intensive Care and Pediatric Surgery, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands.
  • Pokorna P; Department of Pharmacology and Toxicology, Radboud Institute Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Schreuder MF; Pediatric Clinical Research Center, Queen Silvia Children's Hospital, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Standing JF; Institute for Inherited Metabolic Diseases and Department of Pediatrics, Paracelsus Medical University, Clinical Research Center Salzburg, Salzburg, Austria.
  • Turner MA; Institute of Psychiatry and Mental Health, Child and Adolescent Psychiatry Department, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IiSGM, CIBERSAM, Madrid, Spain.
  • Vitiello B; Intensive Care and Pediatric Surgery, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands.
  • Zhao W; Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
  • Weingberg AM; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
  • Willmann R; Department of Physiology and Pharmacology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
  • van den Anker J; Department of Pediatric Nephrology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Amalia Children's Hospital, Nijmegen, the Netherlands.
  • Allegaert K; UCL Great Ormond Street Institute of Child Health, London, UK.
Br J Clin Pharmacol ; 88(12): 4965-4984, 2022 12.
Article em En | MEDLINE | ID: mdl-34180088
Developmental pharmacology describes the impact of maturation on drug disposition (pharmacokinetics, PK) and drug effects (pharmacodynamics, PD) throughout the paediatric age range. This paper, written by a multidisciplinary group of experts, summarizes current knowledge, and provides suggestions to pharmaceutical companies, regulatory agencies and academicians on how to incorporate the latest knowledge regarding developmental pharmacology and innovative techniques into neonatal and paediatric drug development. Biological aspects of drug absorption, distribution, metabolism and excretion throughout development are summarized. Although this area made enormous progress during the last two decades, remaining knowledge gaps were identified. Minimal risk and burden designs allow for optimally informative but minimally invasive PK sampling, while concomitant profiling of drug metabolites may provide additional insight in the unique PK behaviour in children. Furthermore, developmental PD needs to be considered during drug development, which is illustrated by disease- and/or target organ-specific examples. Identifying and testing PD targets and effects in special populations, and application of age- and/or population-specific assessment tools are discussed. Drug development plans also need to incorporate innovative techniques such as preclinical models to study therapeutic strategies, and shift from sequential enrolment of subgroups, to more rational designs. To stimulate appropriate research plans, illustrations of specific PK/PD-related as well as drug safety-related challenges during drug development are provided. The suggestions made in this joint paper of the Innovative Medicines Initiative conect4children Expert group on Developmental Pharmacology and the European Society for Developmental, Perinatal and Paediatric Pharmacology, should facilitate all those involved in drug development.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Farmacologia / Modelos Biológicos Tipo de estudo: Prognostic_studies Limite: Child / Humans / Newborn Idioma: En Revista: Br J Clin Pharmacol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Bélgica

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Farmacologia / Modelos Biológicos Tipo de estudo: Prognostic_studies Limite: Child / Humans / Newborn Idioma: En Revista: Br J Clin Pharmacol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Bélgica